PHILIPPINE biotech company IP-Biotech has entered into an exclusive partnership with Tembusu Healthcare and GenScript Biotech Corporation, which allows the distribution of a breakthrough test kit designed to measure the levels of neutralizing antibodies in recovered Covid-19 patients.
The newly-developed cPass SARS CoV-2 Neutralization Antibody Detection Kit (cPass sVNT Kit) is an essential component in the national testing process to measure neutralizing antibodies in the population. This may help scientists to research if those previously infected are developing immunity to reinfection.
Already have an active account? Log in here.
Continue reading with one of these options:
Continue reading with one of these options:
Premium + Digital Edition
Ad-free access
P 80 per month
(billed annually at P 960)
- Unlimited ad-free access to website articles
- Limited offer: Subscribe today and get digital edition access for free (accessible with up to 3 devices)
TRY FREE FOR 14 DAYS
See details
See details
If you have an active account, log in
here
.